Jan P van Meerbeeck
机构: Universiteit Antwerpen - Universitair Ziekenhuis Antwerpen- Universiteit Gent
每年引用次数
引用次数
引用: 41,022
H-指数: 91
I10-指数 : 297
出版物: 716
O-239 Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data
T. Le Chevalier , A. Brown , R. Natale , G. Scagliotti
Lung Cancer 41
13
2003
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.
Debruyne C , Scagliotti G , Splinter Ta , Ardizzoni A
Oncology 11 11 -14
8
1997
Short-term survival after major pulmonary resections for bronchogenic carcinoma.
Van Schil P , Van Meerbeeck J , Eyskens E , Vanmaele R
Acta Chirurgica Belgica 96 ( 6) 273 -279
14
1996
Massive intestinal haemorrhage due to a solitary jejunal metastasis of a primary bronchogenic tumour.
Hubens G , Van Meerbeeck J , Van Eerdeweg W , Schoofs E
Acta Chirurgica Belgica 92 ( 4) 187 -190
12
1992
Effects of radical treatment in patients with intrathoracic cancer
K. Vermaelen , J.P van Meerbeeck , V.F. Surmont , E. Derom
European Respiratory Journal 40 4161
2012
Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM)
J.W van Haarst , J.A Burgers , C.H Manegold , P Baas
Lung Cancer 29 ( 1) 18 -19
17
2000
Patterns of tumor recurrence following induction chemotherapy and involved-field″ radiotherapy (RT) to 70 Gy in stage 3 non-small cell lung cancer (NSCLC)
J.P van Meerbeeck , S.A Burgers , J van Sornsen de Koste , R.J van Klaveren
Lung Cancer 29 ( 1) 170
2000
Patterns of care for non-small cell lung cancer (NSCLC) patients (PTS) in the Netherlands: An analysis of cancer registry data
J.P van Meerbeeck , C.J.C Meurs , R.A.M Damhuis
Lung Cancer 29 ( 1) 237
1
2000
Management of malignant pleural mesothelioma: have we made any progress?
Van Meerbeeck Jp , Surmont Vf , Hiddinga Bi
Panminerva Medica 55 ( 2) 157 -173
6
2013
Early bronchopleural fistula after lung resection.
Van Meerbeeck Jp , Van Schil Pe
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Università di Napoli, Secondo ateneo 51 ( 5) 421
3
1996
Radiotherapy for single station N2 NSCLC.
P Jan , van Meerbeeck
Translational lung cancer research 3 ( 4) 234 -237
2014
Is an evidence-based approach unrealistic in NSCLC?
Philippe Coucke , Léon Bosquee , Van Meerbeeck , Nicole Barthelemy
Belgian Journal of Medical Oncology [=BJMO] 2 ( 6)
2008
Infections respiratoires chez le patient VIH positif
J. P. Van Meerbeeck , R. Colebunders
Garant
1997
Multimodal management of malignant pleural mesothelioma: where are we today?
P. E. Van Schil , I. Opitz , W. Weder , C. De Laet
European Respiratory Journal 44 ( 3) 754 -764
36
2014
Adjuvant or neoadjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC): How would staging affect the patients (pts) treated?
J. P. Van Meerbeeck , M. Nicholson , D. Gilligan , H. J. Groen
Journal of Clinical Oncology 26 ( 15) 7509 -7509
2
2008
EUS-FNA as staging tool in resectable pleural mesothelioma
S. A. Burgers , K. G. Tournoy , M. Smits , H. M. Klomp
Journal of Clinical Oncology 26 7606 -7606
2008
A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC
J. P. Van Meerbeeck , C. Manegold , R. Gaafar , R. J. van Klaveren
Journal of Clinical Oncology 22 7021 -7021
27
2004
Paclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin - etoposide: A multicenter phase II study
G. Joos , D. Schallier , P. Pinson , M. Sterckx
Journal of Clinical Oncology 22 7211 -7211
11
2004
Occupational risk factors of lung cancer : a hospital based case-control study
J. H. Droste , J. J. Weyler , J. P. Van Meerbeeck , P. A. Vermeire
Occupational and Environmental Medicine 56 ( 5) 322 -327
33
1999
Does downstaging in patients (pts) with IIIA-N2 non-small cell lung cancer (NSCLC) and a response to induction chemotherapy (ICT) influence outcome with surgery (S) or radiotherapy (RT)? An exploratory analysis of EORTC 08941
J. P. Van Meerbeeck , G. W. Kramer , C. Legrand , E. F. Smit
Journal of Clinical Oncology 24 ( 18) 7047 -7047
7
2006